Evotec SE

Evotec SE: Laetitia Rouxel, Restricted shares granted as Short-Term Variable Incentive (Bonus) for 2023 pursuant Evotec’s remuneration system

Evotec and Novo Nordisk enter into technology development partnership to support next-generation cell therapies

Just – Evotec Biologics opens cutting-edge biologics facility – J.POD® Toulouse, France (EU)

Evotec SE: Dr. Christian Wojczewski, buy

Evotec SE: Aurélie Dalbiez, buy

Evotec announces change in Management Board

Evotec SE: Dr. Christian Wojczewski, buy

Evotec SE: Prof. Dr. Iris Löw-Friedrich, buy

Evotec SE: Dr. Christian Wojczewski, buy

Evotec SE: Dr. Craig Johnstone, buy

Evotec SE: Dr. Christian Wojczewski, buy

Evotec SE reports H1 2024 results: Challenging year; priority reset for sustainable profitable growth gaining momentum, building on core strengths

Evotec announces strong progress in strategic protein degradation partnership with Bristol Myers Squibb

Evotec announces progress in strategic neuroscience partnership with Bristol Myers Squibb

Evotec SE reports first half-year 2024 results on 14 August 2024

Evotec provides guidance update

Evotec SE provides guidance update

Correction of a release from 11/07/2024, 14:16 CET/CEST – Evotec SE: Release according to Article 41 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

Release according to Article 41 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

Evotec and Pfizer collaborate to advance drug discovery in France

Just – Evotec Biologics expands tech partnership for biosimilars with Sandoz